The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals Incorporated (VRTX) stock price is 461.68 and Vertex Pharmaceuticals Incorporated (VRTX) 10-day simple moving average is 438.34. Vertex Pharmaceuticals Incorporated (VRTX ...

BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) is set to present pivotal Phase 3 data on suzetrigine, an investigational non-opioid pain signal... ByInvesting.com • Oct ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

In 1977, TAP Pharmaceuticals is formed as a joint venture ... on the New York Stock Exchange on the 2nd January under the symbol "ABBV". "We wish our colleagues at AbbVie continued success as ...

The stock's fall snapped a four-day winning streak.

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...